Provides information on CD20, binding epitopes of anti-CD20 monoclonal antibodies (rituximab, ocrelizumab, ofatumumab, ublituximab) and the effects of anti-CD20 MAbs in multiple sclerosis. Includes slides explaining antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).
Summarizes recent data on the UK (B.1.1.7), Brazil (P.1) and South Africa (B.1.351) variants. Also included are the number of variant cases reported in Canada and the U.S. as of March 9, 2021.
Updates the February 11 slide deck. Includes data on the immune response to SARS-CoV-2, efficacy data for the Oxford-AstraZeneca vaccine, and updates the vaccine recommendations from the Canadian Network of MS Clinics.
Includes the SARS-CoV-2 life cycle, vaccine targets, COVID-19 vaccines in use and in late-stage development, mRNA vaccine phase III data, and the Canadian Network of MS Clinics’ vaccine guidance.